Interferon-alpha therapy of recurrent conjunctival papillomas

Area of Science:

• Ophthalmology
• Virology
• Immunology

Background:

• Recurrent conjunctival papillomas pose a significant clinical challenge.
• Human papillomavirus (HPV) is implicated in the etiology of conjunctival papillomas.

Purpose of the Study:

• To evaluate the efficacy of interferon alpha-N1 in managing multiple, recurrent conjunctival papillomas.

Main Methods:

• Surgical excision followed by a multi-month intramuscular interferon alpha-N1 regimen.
• Dosage: 5 x 10(6) units/m2 daily for one month, then 2-3 times weekly for six months, followed by tapering.
• Follow-up ranged from one to four years.

Main Results:

• Two out of five patients achieved complete remission with no tumor recurrence.
• Three patients experienced recurrences of reduced severity after dose tapering or discontinuation.
• HPV type 11a DNA and koilocytosis were present in most specimens; viral antigens were detected in only two.

Conclusions:

• Interferon alpha-N1 therapy demonstrates tumor-suppressive activity against conjunctival papillomas.
• The treatment regimen appears effective in reducing recurrence severity but is not curative.
• Further research may explore optimized interferon protocols or combination therapies.